why choose us

First received: April 18, 2023

Clinical Trial: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreatic Ductal Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients With KRAS G12D/G12V Mutated Pancreatic Duct

Brief Summary: The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients.The main research objectives are:to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part)to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part)Participants will receive:i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhibitor Ezabenlimab In the second…

Read more